After a successful 30-year career in investment banking and the biopharma industry, Robert F. Carey co-founded ACELYRIN to give back to patients through the identification, development and commercialization of transformative therapeutics. For Bob it isn’t just about the numbers, he is committed to helping people by using the personal wealth he created to enable meaningful philanthropy to give back to patients, society and his community.
Bob’s career spans management, corporate strategy, mergers and acquisitions (M&A) advisory and capital-raising for biotech and pharmaceutical companies. Having begun his career when the biotech industry was relatively young, he developed a deep understanding of the industry’s value chain and became an expert in capital allocation, acquisition strategy, financing, and investor relations.
Bob previously served as executive vice president and chief business officer at Horizon Therapeutics plc, a biopharmaceutical company, where he developed and directed the corporation’s strategy to expand through acquisitions of commercial products and development-stage programs. He and his team completed approximately $3.5 billion in acquisition and licensing transactions, raised approximately $7 billion in debt and equity financing and helped transform Horizon from a $200 million market cap specialty pharma company to a fully integrated, highly profitable biopharma company with a market cap today of over $15 billion. In addition to leading the effort to identify, evaluate, negotiate and close on transactions, he also ran the investor relations function during part of his tenure.
Significant acquisitions and licensing transactions completed while at Horizon included River Vision Development Corp. (TEPEZZA®), Raptor Pharmaceutical Corp. (PROCYSBI®), Crealta Holdings LLC (KRYSTEXXA®), Hyperion Therapeutics, Inc. (RAVICTI®) and Vidara Therapeutics International Ltd. (ACTIMMUNE®).
Before Horizon, Bob started and led the healthcare investment banking group at JMP Securities LLC. Prior to JMP, Bob served as managing director in the healthcare groups at Dresdner Kleinwort Wasserstein, Inc. and Vector Securities International, Inc. Bob has worked with hundreds of biotech companies on M&A and financing transactions with an aggregate value of several billions of dollars. Bob also held roles at Shearson Lehman Hutton and Ernst & Whinney.
Bob serves on the board of directors of Sangamo Therapeutics, Inc., Beyond Air, Inc. and FS Development Corp.
Bob received his BS in accounting from the University of Notre Dame.